Comments
Dr. Reddy’s Laboratories has launched Amoxicillin tablets, capsules, and oral suspension in the US market.
The product is a bio-equivalent generic version of Amoxil (Amoxicillin) tablets, capsules, and oral suspension.
Officially launched on September 17 in the US, Amoxicillin tablets (500 mg and 875 mg), capsules (250 mg and 500 mg), and oral suspension (125 mg/5 ml, 200 mg/5 ml, 250 mg/5 ml, and 400 mg/5 ml) are approved by the United States Food and Drug Administration (US FDA).
In a press release, the Hyderabad-based pharma major said the Amoxil brand and generic tablets (875 mg) has US sales of approximately $22.2 million, capsules ($67.2 m), and oral suspension ($89.5 m), for the 12 months ended June 30, 2012 quoting IMS Health.
Dr. Reddy’s Amoxicillin tablets will be available in bottle counts of 20 and 100; Amoxicillin capsules in bottle counts of 100 and 500 and oral suspension in 200 mg/5 ml and 400 mg/5 ml, in three counts of 50 ml, 75 ml, and 100 ml.
Amoxicillin oral suspension in 125 mg/5 ml and 250 mg/5 ml will be available in bottle sizes of 80 ml, 100 ml, and 150 ml.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.